High prevalence of being Overweight and Obese HIV-infected persons, before and after 24months on early ART in the ANRS 12136 Temprano Trial

AIDS Research and Therapy

Volumn 13, Issue 1, 2016, Pages

  Guehi, Calixte ^b   Badjé, Anani ^a,c   Gabillard, Delphine ^c   Ouattara, Eric ^a,c   Koulé, Serge Olivier ^b   Moh, Raoul ^a,e   Ekouevi, Didier ^a,c   Ahibo, Hugues ^d   N'Takpé, Jean Baptiste ^a   Menan, Gérard Kouamé ^a   Deschamps, Nina ^a   Lecarrou, Jerôme ^c   Eholié, Serge ^a,e   Anglaret, Xavier ^a,c   Danel, Christine ^a,c  

^a Programme PACCI   (Côte d’Ivoire)

^b Unité de Soin Ambulatoire et de Conseil   (Côte d’Ivoire)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^e University Hospital of Treichville   (Côte d’Ivoire)

Author keywords

Africa; Early ART; HIV infection; Obesity

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; HEMOGLOBIN; ISONIAZID; LOPINAVIR; RITONAVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TUBERCULOSTATIC AGENT;

ADULT; AFRICA SOUTH OF THE SAHARA; AGE; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT INDICATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNDERWEIGHT; CLINICAL TRIAL; COMPLICATION; COTE D'IVOIRE; DRUG EFFECTS; HIV INFECTIONS; OVERWEIGHT; TUBERCULOSIS, PULMONARY; WEIGHT REDUCTION;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BODY MASS INDEX; COTE D'IVOIRE; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; OBESITY; OVERWEIGHT; TUBERCULOSIS, PULMONARY; WEIGHT LOSS;

EID: 84959105615     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/s12981-016-0094-y     Document Type: Article

References (52)

1. UNAIDS. Report on the global AIDS epidemic 2014. http://www.unaids.org/sites/default/files/media_asset/AIDS_by_the_numbers_2015_en.pdf Accessed 18 Aug 2015.
2. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children, 2006. http://www.whoint/hiv/pub/guidelines/hivstaging/en/ Accessed 18 Aug 2015.
3. Prevention. CfDCa. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41:1-19.
4. Moss ARBP. Natural History of HIV infection. AIDS. 1989;3:55-61.
5. Mupere E, Malone L, Zalwango S, Chiunda A, Okwera A, Parraga I, et al. Lean tissue mass wasting is associated with increased risk of mortality among women with pulmonary tuberculosis in urban Uganda. Ann Epidemiol. 2012;22:466-73.
6. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-96.
7. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31:1224-9.
8. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24:1228-30.
9. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21:1377-82.
10. Wilson SL, Scullard G, Fidler SJ, Weber JN, Poulter NR. Effects of HIV status and antiretroviral therapy on blood pressure. HIV Med. 2009;6:388-94.
11. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590-8.
12. WHO. Global Health Observatory (GHO): Obesity 2008. World Health Organisation 2013 http://www.whoint/gho/ncd/risk_factors/obesity_text/en/ Accessed 19 Aug 2015.
13. Poirier P, Eckel RH. Obesity and cardiovascular disease. Curr Atheroscler Rep. 2002;4:448-53.
14. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968-76.
15. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918.
16. Crum-Cianflone N, Roediger MP, Eberly L, Headd M, Marconi V, Ganesan A, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS ONE. 2010;5:e10106.
17. Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS. 2008;22:925-30.
18. Crum-Cianflone NF, Roediger M, Eberly LE, Vyas K, Landrum ML, Ganesan A, et al. Obesity among HIV-infected persons: impact of weight on CD4 cell count. AIDS. 2010;24:1069-72.
19. Taylor BS, Liang Y, Garduno LS, Walter EA, Gerardi M, Anstead GM, et al. High Risk of Obesity and Weight Gain for HIV-Infected Uninsured Minorities. J Acquir Immune Defic Syndr. 2014;65:e33-40.
20. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
21. WHO. Antiretroviral therapy for HIV infection in adults and adolescents. 2010, http://www.whoint/hiv/pub/arv/adult2010/en/ , Accessed 18 Aug 2015.
22. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2013. http://www.whoint/hiv/pub/guidelines/arv2013/download/en/ 18 Aug 2015.
23. Koethe JR, Jenkins CA, Lau B, Shepherd BE, Silverberg MJ, Brown TT, et al. Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010. HIV Med. 2015;16:572-7.
24. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21:2483-91.
25. WHO. BMI classification. Global database on Body Mass Index; 2004. http://www.appswhoint/bmi/indexjsp?introPage=intro_3html. Accessed 18 Aug 2015.
26. Sida Mdlsedllcl. Rapport de l'enquête nutritionnelle basée sur la méthodologie SMART; 2010. http://www.ivorycoast.humanitarianresponse.info/LinkClick.aspx?fileticket=dbzs1l-U4ps%3D&tabid=79&mid=677&language=en-US. Accessed May 30 2014.
27. Bashi J, Balestre E, Messou E, Maiga M, Coffie PA, Zannou DM, et al. Time trends in demographic and clinical characteristics of adult patients on HAART initiation in West Africa. Med Mal Infect. 2010;40:449-55.
28. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, Boulle A, et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health. 2008;13:870-9.
29. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS. 2008;22:2291-302.
30. Amorosa V, Synnestvedt M, Gross R, Friedman H, MacGregor RR, Gudonis D, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39:557-61.
31. Duran AC, Almeida LB, Segurado AA, Jaime PC. Diet quality of persons living with HIV/AIDS on highly active antiretroviral therapy. J Hum Nutr Diet. 2008;21:346-50.
32. Hendricks KM, Willis K, Houser R, Jones CY. Obesity in HIV-infection: dietary correlates. J Am Coll Nutr. 2006;25:321-31.
33. Vernay M, Malon A, Oleko A, Salanave B, Roudier C, Szego E, et al. Association of socioeconomic status with overall overweight and central obesity in men and women: the French Nutrition and Health Survey 2006. BMC Public Health. 2009;9:215.
34. Ziraba AK, Fotso JC, Ochako R. Overweight and obesity in urban Africa: a problem of the rich or the poor? BMC Public Health. 2009;9:465.
35. Institut National de la Statistique (INS) eII. Enquête démographique et de santé et à indicateurs multiples de Côte d'Ivoire 2011-2012. http://www.dhsprogramcom/pubs/pdf/FR272/FR272pdf. Accessed 18 May 2014.
36. Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, et al. Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2015;53:952-60.
37. Bouchard C. Genetics of obesity in humans: current issues. Ciba Found Symp. 1996;201:108-15.
38. Bouchard C. The causes of obesity: advances in molecular biology but stagnation on the genetic front. Diabetologia. 1996;39:1532-3.
39. Bouchard C, Despres JP, Mauriege P. Genetic and nongenetic determinants of regional fat distribution. Endocr Rev. 1993;14:72-93.
40. Perusse L, Chagnon YC, Dionne FT, Bouchard C. The human obesity gene map: the 1996 update. Obes Res. 1997;5:49-61.
41. Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;1:CD003987.
42. Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60:1852-9.
43. Koethe JR, Grome H, Jenkins CA, Kalams SA, Sterling TR. The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy. AIDS. 2015;30:83-91.
44. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71-82.
45. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097-105.
46. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17:961-9.
47. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640-9.
48. Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation. 2008;117:1658-67.
49. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfield SB. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr. 2002;76:743-9.
50. Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, et al. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. J Acquir Immune Defic Syndr. 2013;62:555-61.
51. Faber M, Kruger HS. Dietary intake, perceptions regarding body weight, and attitudes toward weight control of normal weight, overweight, and obese Black females in a rural village in South Africa. Ethn Dis. 2005;15:238-45.
52. Kiawi E, Edwards R, Shu J, Unwin N, Kamadjeu R, Mbanya JC. Knowledge, attitudes, and behavior relating to diabetes and its main risk factors among urban residents in Cameroon: a qualitative survey. Ethn Dis. 2006;16:503-9.